- Home
- CNR vs APLS Comparison
CNR vs APLS Comparison
Compare CNR & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- APLS
- Stock Information
- Founded
- CNR 1864
- APLS 2009
- Country
- CNR United States
- APLS United States
- Employees
- CNR N/A
- APLS N/A
- Industry
- CNR Coal Mining
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- APLS Health Care
- Exchange
- CNR Nasdaq
- APLS Nasdaq
- Market Cap
- CNR 3.8B
- APLS 3.5B
- IPO Year
- CNR N/A
- APLS 2017
- Fundamental
- Price
- CNR $72.92
- APLS $25.03
- Analyst Decision
- CNR Strong Buy
- APLS Buy
- Analyst Count
- CNR 4
- APLS 20
- Target Price
- CNR $94.75
- APLS $34.11
- AVG Volume (30 Days)
- CNR 628.0K
- APLS 2.1M
- Earning Date
- CNR 08-05-2025
- APLS 11-04-2025
- Dividend Yield
- CNR 0.55%
- APLS N/A
- EPS Growth
- CNR N/A
- APLS N/A
- EPS
- CNR 0.51
- APLS N/A
- Revenue
- CNR $3,275,589,000.00
- APLS $754,649,000.00
- Revenue This Year
- CNR $92.77
- APLS $20.59
- Revenue Next Year
- CNR $9.20
- APLS N/A
- P/E Ratio
- CNR $141.65
- APLS N/A
- Revenue Growth
- CNR 47.13
- APLS 20.02
- 52 Week Low
- CNR $58.19
- APLS $16.10
- 52 Week High
- CNR $134.59
- APLS $39.51
- Technical
- Relative Strength Index (RSI)
- CNR 50.09
- APLS 43.80
- Support Level
- CNR $71.83
- APLS $27.26
- Resistance Level
- CNR $75.67
- APLS $28.97
- Average True Range (ATR)
- CNR 2.18
- APLS 0.99
- MACD
- CNR 0.10
- APLS -0.59
- Stochastic Oscillator
- CNR 50.85
- APLS 6.70
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.